Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/25265
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | de Boer, Richard | - |
dc.contributor.author | Hui, Rina | - |
dc.contributor.author | Lim, Elgene | - |
dc.contributor.author | Yeo, Belinda | - |
dc.contributor.author | Zdenkowski, Nicholas | - |
dc.date | 2020-11 | - |
dc.date.accessioned | 2020-11-10T03:07:39Z | - |
dc.date.available | 2020-11-10T03:07:39Z | - |
dc.date.issued | 2020-11 | - |
dc.identifier.citation | Asia-Pacific Journal of Clinical Oncology 2020; 16 Suppl 5: 3-14 | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/25265 | - |
dc.description.abstract | Treatment strategies for hormone receptor-positive (HR+ ), human epidermal growth factor receptor 2-negative (HER2- ) metastatic breast cancer in young women (<40 years at diagnosis) have traditionally been extrapolated from data obtained from trials conducted either exclusively or predominantly in the postmenopausal setting. These young patients are usually treated with ovarian function suppression (OFS) + endocrine therapy (ET) ± targeted therapy, except if there is a concern about endocrine resistance or a need to gain rapid disease control due to the onset of visceral crisis. This review examines evidence that supports the use of a cyclin-dependent kinase 4/6 inhibitor, in combination with OFS and ET, when treating premenopausal or perimenopausal women with HR+ /HER2- metastatic breast cancer. This includes data from the MONALEESA-7 study (treating only premenopausal/perimenopausal women in the first-line setting), and the results of subgroup analyses from the PALOMA-3 and MONARCH-2 trials. We also consider a number of age-specific challenges that younger breast cancer patients can face, highlighting the importance of a multidisciplinary approach to ongoing care. | en |
dc.language.iso | eng | |
dc.subject | CDK4/6 inhibitor | en |
dc.subject | HER2-negative | en |
dc.subject | endocrine therapy | en |
dc.subject | hormone receptor-positive | en |
dc.subject | metastatic breast cancer | en |
dc.subject | psychosocial | en |
dc.subject | supportive care | en |
dc.subject | younger women | en |
dc.title | Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Asia-Pacific Journal of Clinical Oncology | en |
dc.identifier.affiliation | Epworth-Freemasons Private Hospital, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Westmead Hospital, Westmead, Sydney, New South Wales, Australia | en |
dc.identifier.affiliation | Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | University of Newcastle, Newcastle, New South Wales, Australia | en |
dc.identifier.affiliation | Lake Macquarie Private Hospital, Gateshead, New South Wales, Australia | en |
dc.identifier.affiliation | Breast Cancer Trials, Newcastle, New South Wales, Australia | en |
dc.identifier.affiliation | Austin Health | en |
dc.identifier.affiliation | Olivia Newton-John Cancer Research Institute | en |
dc.identifier.affiliation | St. Vincent's Clinical School, University of New South Wales, Darlinghurst, Sydney, New South Wales, Australia | en |
dc.identifier.affiliation | Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia | en |
dc.identifier.affiliation | University of Sydney, Camperdown, Sydney, New South Wales, Australia | en |
dc.identifier.doi | 10.1111/ajco.13461 | en |
dc.type.content | Text | en |
dc.identifier.pubmedid | 33137857 | |
local.name.researcher | Yeo, Belinda | |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
crisitem.author.dept | Medical Oncology | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.